HUM Q3 2026 deep dive: membership gains and margin recovery offset softer guidance

Health insurance company Humana (NYSE:HUM) reported Q3 2026 results exceeding the market’s revenue expectations, with sales up 26.1% year on year to $41.16 billion. On the other hand, the company’s full-year revenue guidance of $160 billion at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP loss of $0.70 per share was 30.3% above analysts’ consensus estimates.

Is now the time to buy HUM? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Humana’s third quarter results were well received by the market, with management pointing to strong execution across Medicare Advantage and ongoing progress in operational transformation. CEO Jim Rechtin highlighted that both new and existing member performance was meeting or exceeding internal benchmarks, while retention of members affected by plan exits was particularly robust. On the call, Rechtin attributed membership gains to better product positioning and enhanced partnerships with distribution channels, emphasizing, “our recapture or retention of our members impacted by plan exits has been particularly strong.”

Looking ahead, Humana’s updated guidance is anchored by anticipated improvements in Medicare Advantage margins and sustained operational discipline, despite management noting higher healthcare cost trends in the coming year. CFO Celeste Mellet stressed that pricing and ongoing transformation initiatives will be central to margin expansion, stating, “the real incremental progress is going to be because of the pricing.” Management also expects a one-time Stars program tailwind to benefit 2028, but emphasized that margin improvements in the near term will depend on execution in both cost control and benefit design.

Key insights from management’s remarks

Management cited strong member retention, operational efficiency, and effective benefit design as key drivers of the quarter’s performance, while noting that Medicare Advantage margin expansion remains a core priority.

• Membership retention and growth: Management credited strong recapture of members impacted by plan exits, and noted that improved relationships with broker partners were translating into outsized gains through the annual enrollment period (AEP).
• Stars program performance: Humana achieved its highest-ever member-weighted Stars rating, with CEO Jim Rechtin noting a 4.17 average and highlighting the impact on both clinical outcomes and financial performance. The Stars program, which measures plan quality and member satisfaction, is critical for bonus payments and competitive positioning in Medicare Advantage.
• Operational transformation: CFO Celeste Mellet described ongoing multi-year cost transformation as a major contributor to margin recovery, citing specific improvements in inpatient cost trends and value-based care partnerships. The company emphasized its disciplined approach to benefit design and cost structure, aiming to consistently support a 3%+ margin in Medicare Advantage over time.
• Medicaid and CenterWell expansion: Humana’s Medicaid membership grew through six new state contracts in recent years, now spanning 13 states. The CenterWell Primary Care segment saw 30% growth, bolstered by the acquisition of MaxHealth and a new joint venture with BlackRock to enhance balance sheet efficiency.
• Capital allocation flexibility: Recent balance sheet initiatives, including the Gentiva divestiture and the BlackRock joint venture, have reduced debt-to-capital ratios and provided greater flexibility for future investments in Medicaid and CenterWell, as well as potential increases in dividends or share repurchases.

Drivers of future performance

Management expects future performance to be shaped by pricing discipline, cost control, and the evolving healthcare cost environment.

• Pricing and benefit design: CFO Celeste Mellet emphasized that pricing actions taken for 2027 bids, especially in response to higher expected healthcare costs in Part D (prescription drug coverage), will be a primary driver of margin expansion. She noted that “a large part of [margin improvement] is going to be driven by the pricing.”
• Operational cost transformation: Continued focus on reducing operating expenses and improving medical cost outcomes, particularly through value-based care arrangements and network management, is expected to support sustainable profitability. Management highlighted that transformation initiatives already offset much of the Stars headwind and will remain a source of incremental improvement.
• Tailwinds from Stars ratings: The company anticipates a one-time margin tailwind in 2028 from exceptional Stars program results, though management cautioned that only part of this will be reinvested in growth or returned to shareholders, with the remainder flowing to earnings as conditions allow.

Catalysts in upcoming quarters

Looking ahead, our analysts will be monitoring (1) Humana’s ability to sustain Medicare Advantage margin improvements as new pricing and benefit design strategies take effect, (2) the impact of operational transformation on both medical and operating costs, and (3) how Medicaid and CenterWell Primary Care expansion contribute to overall earnings growth. Updates on the scale and use of the anticipated Stars tailwind will also be important milestones.

Humana currently trades at $432.87, up from $411.88 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.